Drugmaker-Sponsored Research Shows Xarelto Especially Dangerous for At-Risk Pulmonary Embolism Patients

Xarelto patients at higher risk for pulmonary embolisms (PE) have a significantly elevated chance of a major bleeding event or death than those with lower PE likelihoods, according to research sponsored by the anticoagulant’s manufacturers Bayer and Janssen Pharmaceuticals. A study published in the March 2015 issue of Academic Emergency Medicine examining 5,000 patients taking Xarelto showed that at-risk PE subjects were 2 times more likely to experience a recurrent venous thromboembolism and 5 times more likely to experience a fatal pulmonary embolism. High PE risk factors also showed that Xarelto use led to a 4 times greater chance of death and a 2 times greater chance of a major bleeding event. Due to the lack of an antidote to stop a major bleed, Xarelto is dangerous and potentially deadly for users with all risk factors, but may be especially hazardous to patients at high-risk for PE.

Real Time Analytics